Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ADC Therapeutics SA ADCT

Healthcare Biotechnology
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The... see more

Recent & Breaking News (NYSE:ADCT)

ADC Therapeutics Announces CEO Transition

Business Wire May 9, 2022

ADC Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates

Business Wire May 9, 2022

ADC Therapeutics to Present at the BofA Securities 2022 Healthcare Conference

Business Wire May 4, 2022

ADC Therapeutics to Host First Quarter 2022 Financial Results Conference Call on May 9, 2022

Business Wire May 3, 2022

ADC Therapeutics Receives Permanent J-Code for ZYNLONTA® (J9359) from U.S. Centers for Medicare & Medicaid Services

Business Wire April 4, 2022

ADC Therapeutics Releases its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2021

Business Wire March 17, 2022

ADC Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates

Business Wire March 3, 2022

ADC Therapeutics to Participate in Cowen's 42nd Annual Health Care Conference

Business Wire March 1, 2022

ADC Therapeutics to Host Fourth Quarter and Year-End 2021 Financial Results Conference Call on March 3, 2022

Business Wire February 24, 2022

ADC Therapeutics Releases its Inaugural Environmental, Social and Governance Report

Business Wire February 17, 2022

ADC Therapeutics Highlights its Proprietary ADC Platform and Solid Tumor Pipeline

Business Wire February 8, 2022

ADC Therapeutics to Participate in Guggenheim Oncology Conference

Business Wire February 2, 2022

ADC Therapeutics to Host Webcast Highlighting its ADC Platform and Solid Tumor Pipeline on February 8, 2022

Business Wire January 20, 2022

ADC Therapeutics Announces Exclusive License with Mitsubishi Tanabe Pharma Corporation to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Japan

Business Wire January 18, 2022

ADC Therapeutics to Participate in the Jefferies London Healthcare Conference

Business Wire November 9, 2021

ADC Therapeutics Announces Abstracts to be Presented at the 63rd ASH Annual Meeting

Business Wire November 4, 2021

ADC Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates

Business Wire November 2, 2021

ADC Therapeutics Announces Validation of its Marketing Authorization Application by the European Medicines Agency for ZYNLONTA®

Business Wire October 29, 2021

ADC Therapeutics to Host Third Quarter 2021 Financial Results Conference Call on November 2, 2021

Business Wire October 27, 2021

Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA® in Pivotal Phase 2 Clinical Trial for Diffuse Large B-cell Lymphoma

Business Wire September 29, 2021